Page 104 - 《中国药房》2023年3期
P. 104

·药物与临床·


          基于美国FAERS数据库的利培酮不良事件信号挖掘与分析
                                                                                                     Δ

                                                   2 #
                                           1
                 1*
          黄 玲 ,王凤玲 ,陈 力 ,王新茗 ,陈 力 (1.成都医学院第一附属医院药学部,成都 610500;2.四川大学
                           1
                                   1
          华西第二医院药学部,成都 610041)
          中图分类号  R969.3;R971      文献标志码  A      文章编号  1001-0408(2023)03-0350-05
          DOI  10.6039/j.issn.1001-0408.2023.03.18

          摘   要  目的  为利培酮的临床安全使用提供参考。方法  采用报告比值比法与英国药品和保健品管理局综合标准法,对美国
          FDA不良事件报告系统(FAERS)数据库中2017年第1季度至2021年第3季度共19个季度的利培酮相关药品不良事件(ADE)报
          告进行数据挖掘与分析。结果  获得以利培酮为首要怀疑药物的 ADE 报告共计 101 181 份,涉及患者 33 179 例。所统计的报告
          中,男女比约为 6.21∶1;以<18 岁的患者居多(占 15.01%);上报 ADE 者主要为消费者(占 69.74%),上报国家主要为美国(占
          79.72%);使用口服剂型的患者最多(占83.71%)。共产生ADE信号409个,包括男性乳腺发育、假性男性乳房发育症、体质量异常
          增加、高催乳素血症和Wellens综合征等;涉及26个系统器官分类,主要为生殖系统及乳腺疾病,各类损伤、中毒及操作并发症,精
          神病类,代谢及营养类疾病,各类神经系统疾病等。结论  利培酮常见ADE信号及其累及系统器官与说明书基本一致,但也要警
          惕其说明书中未记载的ADE,如Wellens综合征、纤维增生性心内膜炎、门静脉海绵样变性、兔子综合征等。
          关键词  利培酮;药品不良事件;信号;数据挖掘;药品不良反应

          Mining and analysis of risperidone adverse event signals based on FAERS database
                                                                              2
                                                                    1
                                                   1
          HUANG Ling ,WANG Fengling ,CHEN Li ,WANG Xinming ,CHEN Li(1.  Dept.  of  Pharmacy,the  First
                       1
                                        1
          Affiliated  Hospital  of  Chengdu  Medical  College,Chengdu  610500,China;2.  Dept.  of  Pharmacy,West  China
          Second University Hospital,Sichuan University,Chengdu 610041,China)
          ABSTRACT    OBJECTIVE  To  provide  reference  for  safe  use  of  risperidone  in  clinic.  METHODS  Data  mining  and  analysis  of
          risperidone-related adverse drug event (ADE) reports from the first quarter of 2017 to the third quarter of 2021 in the United States
          FAERS database were carried out using reported odds ratio and composite criteria methods from Medicines and Healthcare Products
          Regulatory Agency. RESULTS  There were 101 181 ADE reports with risperidone as the primary suspect drug,involving a total of
          33 179 patients. Among those reports,the male-to-female ratio was about 6.21 to 1; most of them were <18 years old (15.01%);
          ADE was mainly reported by consumers (69.74%) and mainly reported by the United States (79.72%); oral dosage form was the
          most  used,accounting  for  83.71%.  A  total  of  409  ADE  signals  were  obtained,including  male  breast  development,
          pseudogynecomastia,abnormal increase in body mass,hyperprolactinemia and Wellens syndrome,etc. Twenty-six systems and organs
          were  involved,mainly  including  reproductive  system  and  breast  diseases,various  injuries,poisoning  and  operational  complications,
          mental  diseases,metabolic  and  nutritional  diseases,and  various  nervous  system  diseases,etc.  CONCLUSIONS  The  common ADE
          signals  of  risperidone  and  the  system  involved  are  consistent  with  the  instructions,but  we  should  also  be  alert  to  the  ADE  not
          recorded  in  the  instruction,such  as  Wellens  syndrome,fibroproliferative  endocarditis,cavernous  degeneration  of  portal  vein,rabbit
          syndrome,etc.
          KEYWORDS     risperidone; adverse drug events; signal; data mining; adverse drug reaction



              流行病学和经济学研究表明,精神疾病的全球负担                          失。根据2019年全球疾病负担(global burden of disease,
          相当沉重,无论是对人类健康的影响还是社会福利的损                            GBD)研究结果,超过 1.25 亿伤残调整生命年归因于精
                                                                                           [1]
                                                              神障碍,约占全球疾病负担的 5% 。当前,临床治疗精
              Δ 基金项目 四川省科技计划项目(No.2019JDR0163);四川省医
          学(青年创新)科研课题(No.Q21072)                              神疾病仍以药物治疗为主,主要包括第一代抗精神病药
             * 第一作者 主 管 药 师 。 研 究 方 向 :临 床 药 学 。 E-mail:      物(first-generation antipsychotics,FGAs)和第二代抗精
          542947085@qq.com
                                                              神病药物(second-generation antipsychotics,SGAs)两类。
              # 通信作者 副主任药师,硕士。研究方向:临床药学与医院合理
          用药。E-mail:13674852@qq.com                           其中,SGAs因为具有较好的治疗效果和较低的副作用,


          · 350 ·    China Pharmacy  2023 Vol. 34  No. 3                               中国药房  2023年第34卷第3期
   99   100   101   102   103   104   105   106   107   108   109